Related Experiment Video

Updated: May 27, 2026

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
08:34

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer

Published on: April 13, 2015

Abnormal MDMX degradation in tumor cells due to ARF deficiency

X Li1, D Gilkes, B Li

  • 1Molecular Oncology Department, Moffitt Cancer Center, Tampa, FL, USA.

Oncogene
|November 29, 2011
PubMed

Insights

Loss of alternate reading frame (ARF) in tumor cells prevents MDM2 from degrading MDMX, compromising p53 activity. Restoring ARF enables MDM2 to degrade MDMX, impacting cancer therapy strategies.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Cellular Regulation

Background:

  • MDMX is a key regulator of p53, often elevated in tumors, leading to p53 inactivation.
  • MDMX degradation is primarily mediated by MDM2-dependent ubiquitination.
  • Tumor cells frequently exhibit loss of alternate reading frame (ARF) expression, a critical factor in p53 pathway regulation.

Purpose of the Study:

  • To investigate the impact of ARF expression on MDMX turnover and MDM2-mediated degradation.
  • To elucidate the mechanism by which ARF influences the interaction between MDMX and MDM2.
  • To understand how ARF deficiency in tumors affects the p53 regulatory pathway and potential therapeutic interventions.

Main Methods:

  • Comparative analysis of MDMX turnover in non-transformed versus tumor cells with varying ARF expression levels.
  • Biochemical assays to assess MDMX-MDM2 binding and ubiquitination.
  • Investigation of ARF's role in modulating the interaction between MDM2 and MDMX.

Main Results:

  • MDMX turnover is sensitive to MDM2 levels in non-transformed cells but not in tumor cells lacking ARF.
  • Loss of ARF significantly diminishes MDMX sensitivity to MDM2-mediated degradation.
  • ARF binds to MDM2, promoting a secondary interaction site with MDMX, thereby enhancing MDMX ubiquitination and degradation.

Conclusions:

  • ARF deficiency in tumors disrupts the p53-regulatory pathway by causing MDMX accumulation.
  • Loss of ARF compromises p53 activity and may limit the effectiveness of MDM2-specific inhibitors.
  • Restoration of ARF expression in tumor cells re-sensitizes MDMX to MDM2-mediated degradation.

More Related Videos

Assessing Functional Performance in the Mdx Mouse Model10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...